GE Healthcare Technologies Inc
NASDAQ:GEHC
GE Healthcare Technologies Inc
GE Healthcare Technologies Inc. operates as a pivotal player in the vast landscape of medical technology, skillfully weaving a narrative that integrates cutting-edge innovation with practical application. As a segment originally spun out from the iconic General Electric Company, GE Healthcare focuses on enhancing diagnostics and patient care through its advanced imaging and monitoring systems. The company's portfolio spans a wide range of products, including magnetic resonance imaging (MRI) machines, ultrasound devices, and computed tomography (CT) scanners, each designed to provide medical professionals with critical insights needed for accurate diagnosis and effective treatment. By leveraging decades of engineering expertise and a rich history in innovation, GE Healthcare not only improves hospital efficiencies but also supports personalized healthcare solutions that help in the early detection and effective management of diseases.
Their revenue model is primarily centered around the sale of these high-technology machines and the accompanying service agreements that ensure their seamless operation. Additionally, the company generates income from its work in life sciences, offering a suite of applications and software that assist in drug discovery and bioprocessing. Combining hardware sales with recurring revenue streams from maintenance services and digital solutions enhances the company’s financial stability. This multifaceted approach positions GE Healthcare as both a stalwart in existing medical technology fields and a pioneer exploring the frontiers of healthcare innovations, driven by a mission to improve patient outcomes worldwide.
GE Healthcare Technologies Inc. operates as a pivotal player in the vast landscape of medical technology, skillfully weaving a narrative that integrates cutting-edge innovation with practical application. As a segment originally spun out from the iconic General Electric Company, GE Healthcare focuses on enhancing diagnostics and patient care through its advanced imaging and monitoring systems. The company's portfolio spans a wide range of products, including magnetic resonance imaging (MRI) machines, ultrasound devices, and computed tomography (CT) scanners, each designed to provide medical professionals with critical insights needed for accurate diagnosis and effective treatment. By leveraging decades of engineering expertise and a rich history in innovation, GE Healthcare not only improves hospital efficiencies but also supports personalized healthcare solutions that help in the early detection and effective management of diseases.
Their revenue model is primarily centered around the sale of these high-technology machines and the accompanying service agreements that ensure their seamless operation. Additionally, the company generates income from its work in life sciences, offering a suite of applications and software that assist in drug discovery and bioprocessing. Combining hardware sales with recurring revenue streams from maintenance services and digital solutions enhances the company’s financial stability. This multifaceted approach positions GE Healthcare as both a stalwart in existing medical technology fields and a pioneer exploring the frontiers of healthcare innovations, driven by a mission to improve patient outcomes worldwide.
Q4 and FY Performance: GE HealthCare reported strong Q4 results, with $5.7 billion in revenue, growing 4.8% organically year-over-year, and full-year revenue of $20.6 billion, up 3.5% organically—both beating expectations.
Profitability: Q4 adjusted EBIT margin was 16.7%, down 200 basis points due to tariffs and mix, while adjusted EPS was $1.44 (down 0.7%) impacted by tariffs. Free cash flow in Q4 was $916 million, up $105 million.
Record Backlog: Ended Q4 with a record backlog of $21.8 billion (up $2 billion YoY), and a book-to-bill of 1.06x, signaling strong future demand.
2026 Guidance: Management guided to 3–4% organic revenue growth, adjusted EBIT margin of 15.8–16.1%, adjusted EPS of $4.95–$5.15 (up 8–12%), and free cash flow of $1.7 billion (up 13%) for 2026.
Product Innovation: Nine major new product launches are pending regulatory approval, expected to drive future orders and revenue, with significant impact anticipated in 2027.
Flyrcado Update: Flyrcado rollout is progressing, with on-time delivery now at 95% and dose numbers expected to ramp throughout 2026; confidence in reaching $500 million revenue by 2028 remains.
Tariff Mitigation: Significant actions were taken to offset tariff impacts in 2025, and further improvements are expected in 2026.
China Outlook: Guidance for 2026 assumes a decline in China, reflecting a prudent and cautious approach despite some recent commercial improvements.
